Cited 10 times in
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2023-08-09T02:35:15Z | - |
dc.date.available | 2023-08-09T02:35:15Z | - |
dc.date.issued | 2017-04 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195649 | - |
dc.description.abstract | Purpose: Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials. Materials and methods: In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease. Results: A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively. Conclusion: This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents / administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents / adverse effects | - |
dc.subject.MESH | Antineoplastic Agents / therapeutic use* | - |
dc.subject.MESH | Biomarkers, Tumor | - |
dc.subject.MESH | Breast Neoplasms / drug therapy* | - |
dc.subject.MESH | Breast Neoplasms / mortality | - |
dc.subject.MESH | Breast Neoplasms / pathology* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Furans / administration & dosage | - |
dc.subject.MESH | Furans / adverse effects | - |
dc.subject.MESH | Furans / therapeutic use* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ketones / administration & dosage | - |
dc.subject.MESH | Ketones / adverse effects | - |
dc.subject.MESH | Ketones / therapeutic use* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retreatment | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yeon Hee Park | - |
dc.contributor.googleauthor | Tae Yong Kim | - |
dc.contributor.googleauthor | Young-Hyuck Im | - |
dc.contributor.googleauthor | Keun-Seok Lee | - |
dc.contributor.googleauthor | In Hae Park | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Soo-Hyeon Lee | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Jee Hyun Kim | - |
dc.contributor.googleauthor | Se Hyun Kim | - |
dc.contributor.googleauthor | Soo Jung Lee | - |
dc.contributor.googleauthor | Su-Jin Koh | - |
dc.contributor.googleauthor | Ki Hyeong Lee | - |
dc.contributor.googleauthor | Yoon Ji Choi | - |
dc.contributor.googleauthor | Eun Kyung Cho | - |
dc.contributor.googleauthor | Suee Lee | - |
dc.contributor.googleauthor | Seok Yun Kang | - |
dc.contributor.googleauthor | Jae Hong Seo | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Kyung Hae Jung | - |
dc.identifier.doi | 10.4143/crt.2016.191 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A03484 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 27488876 | - |
dc.subject.keyword | Breast neoplasms | - |
dc.subject.keyword | Eribulin | - |
dc.subject.keyword | Korean | - |
dc.subject.keyword | Metastasis | - |
dc.subject.keyword | Phase IV clinical trial | - |
dc.subject.keyword | Safety | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 423 | - |
dc.citation.endPage | 429 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.49(2) : 423-429, 2017-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.